Posted by Michael Wonder on 27 May 2020
NICE recommends treatment for type of small-cell lung cancer
27 May 2020 - A new treatment option for patients with extensive-stage small-cell lung cancer has been approved by NICE.
In new draft guidance, atezolizumab (also called Tecentriq and made by Roche) with carboplatin and etoposide has been recommended as an option for untreated extensive-stage small-cell lung cancer (ES-SCLC).
Around 2400 people in England have ES-SCLC, of whom around 1200 people will be eligible for treatment with atezolizumab with carboplatin and etoposide.
